CONMED Q4 Revenue $373.2M Exceeds Consensus
Reports Q4 revenue $373.2M, consensus $366.88M. "Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long-term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair."
Trade with 70% Backtested Accuracy
Analyst Views on CNMD
About CNMD
About the author
CONMED Corporation Q4 2025 Earnings Call Insights
- Sales Growth: CONMED reported total sales of $373.2 million for Q4 2025, reflecting a year-over-year increase of 7.9%, with full-year sales reaching $1.375 billion, indicating stable growth potential in the medical device market.
- Strategic Shift: The company announced its exit from gastroenterology product lines, which is expected to improve long-term consolidated gross margins by approximately 80 basis points, demonstrating a focus on higher-growth business areas.
- Supply Chain Improvement: In sports medicine, CONMED reported back order values and SKU counts at a three-year low, indicating significant progress in resolving supply chain constraints, which is expected to further drive future performance.
- Future Outlook: Management is guiding for 2026 revenue between $1.345 billion and $1.375 billion, with adjusted EPS between $4.30 and $4.45, reflecting confidence in future growth and a commitment to ongoing investments.
CONMED (CNMD) Q4 2025 Earnings Call Transcript
CONMED (CNMD) Experiences Oversold Conditions
CONMED Corp Trading Update: Shares of CONMED Corp (CNMD) have entered oversold territory with an RSI reading of 29.5, indicating potential exhaustion of recent selling pressure.
Current Share Price and Performance: The stock traded as low as $38.83, with a current price of $38.99, while its 52-week range is between $38.83 and $76.34.
Investor Sentiment: Bullish investors may view the low RSI as an opportunity to consider buying, anticipating a potential rebound in the stock's performance.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio
CONMED's Strategic Shift: CONMED announced its exit from gastroenterology product lines, including an early termination of its distribution agreement with Gore for the VIABIL biliary stent, to focus on core areas like minimally invasive and orthopedic soft tissue surgery.
Financial Impact: The company expects a revenue loss of $90–$95 million from the gastroenterology segment in 2025 and anticipates earnings per share dilution of 45–55 cents in 2026, but aims to improve its gross margin profile by about 80 basis points in the long run.
Market Reaction: Following the announcement, CONMED's shares fell over 9%, reflecting investor concerns, as the company has seen a 41.5% decline in stock value year-to-date compared to industry growth.
Future Outlook: The exit is expected to streamline CONMED’s operations, enhance profitability, and allow for better resource allocation towards higher-growth potential areas, ultimately aiming for a more resilient business model.
Examining CONMED's Story Following Adjustments in Analyst Models and Financial Strategies
Fair Value and Analyst Perspectives: CONMED's fair value remains steady at $54.00 per share, with analysts adjusting growth and risk assumptions, reflecting a balanced view of execution risk while maintaining a positive outlook on operational efficiency and cost control.
Strategic Changes and Financial Moves: The company announced a new share repurchase program of up to $150 million, indicating confidence in its valuation, while also tightening its revenue guidance for 2025 and suspending its quarterly cash dividend to prioritize buybacks.
Market Dynamics and Analyst Sentiment: Analysts from firms like JPMorgan and Barclays remain bullish on CONMED, citing favorable trends in demand and disciplined expense management, while others like Truist and Citi express caution due to potential near-term challenges affecting valuation.
Community Engagement and Future Outlook: Investors are encouraged to engage with the Simply Wall St Community to track evolving narratives around CONMED, including trends in minimally invasive surgery, operational improvements, and the impact of buybacks on stock valuation.
CONMED (CNMD) Surpasses 2% Yield Threshold
Dividend Predictability: Dividend amounts are generally unpredictable and fluctuate based on a company's profitability.
CONMED Corp Analysis: Analyzing CONMED Corp's historical dividend chart can provide insights into the likelihood of maintaining a 2% annual yield.
CONMED Corporation Q4 2025 Earnings Call Insights
- Sales Growth: CONMED reported total sales of $373.2 million for Q4 2025, reflecting a year-over-year increase of 7.9%, with full-year sales reaching $1.375 billion, indicating stable growth potential in the medical device market.
- Strategic Shift: The company announced its exit from gastroenterology product lines, which is expected to improve long-term consolidated gross margins by approximately 80 basis points, demonstrating a focus on higher-growth business areas.
- Supply Chain Improvement: In sports medicine, CONMED reported back order values and SKU counts at a three-year low, indicating significant progress in resolving supply chain constraints, which is expected to further drive future performance.
- Future Outlook: Management is guiding for 2026 revenue between $1.345 billion and $1.375 billion, with adjusted EPS between $4.30 and $4.45, reflecting confidence in future growth and a commitment to ongoing investments.
CONMED (CNMD) Q4 2025 Earnings Call Transcript
CONMED (CNMD) Experiences Oversold Conditions
CONMED Corp Trading Update: Shares of CONMED Corp (CNMD) have entered oversold territory with an RSI reading of 29.5, indicating potential exhaustion of recent selling pressure.
Current Share Price and Performance: The stock traded as low as $38.83, with a current price of $38.99, while its 52-week range is between $38.83 and $76.34.
Investor Sentiment: Bullish investors may view the low RSI as an opportunity to consider buying, anticipating a potential rebound in the stock's performance.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio
CONMED's Strategic Shift: CONMED announced its exit from gastroenterology product lines, including an early termination of its distribution agreement with Gore for the VIABIL biliary stent, to focus on core areas like minimally invasive and orthopedic soft tissue surgery.
Financial Impact: The company expects a revenue loss of $90–$95 million from the gastroenterology segment in 2025 and anticipates earnings per share dilution of 45–55 cents in 2026, but aims to improve its gross margin profile by about 80 basis points in the long run.
Market Reaction: Following the announcement, CONMED's shares fell over 9%, reflecting investor concerns, as the company has seen a 41.5% decline in stock value year-to-date compared to industry growth.
Future Outlook: The exit is expected to streamline CONMED’s operations, enhance profitability, and allow for better resource allocation towards higher-growth potential areas, ultimately aiming for a more resilient business model.
Examining CONMED's Story Following Adjustments in Analyst Models and Financial Strategies
Fair Value and Analyst Perspectives: CONMED's fair value remains steady at $54.00 per share, with analysts adjusting growth and risk assumptions, reflecting a balanced view of execution risk while maintaining a positive outlook on operational efficiency and cost control.
Strategic Changes and Financial Moves: The company announced a new share repurchase program of up to $150 million, indicating confidence in its valuation, while also tightening its revenue guidance for 2025 and suspending its quarterly cash dividend to prioritize buybacks.
Market Dynamics and Analyst Sentiment: Analysts from firms like JPMorgan and Barclays remain bullish on CONMED, citing favorable trends in demand and disciplined expense management, while others like Truist and Citi express caution due to potential near-term challenges affecting valuation.
Community Engagement and Future Outlook: Investors are encouraged to engage with the Simply Wall St Community to track evolving narratives around CONMED, including trends in minimally invasive surgery, operational improvements, and the impact of buybacks on stock valuation.
CONMED (CNMD) Surpasses 2% Yield Threshold
Dividend Predictability: Dividend amounts are generally unpredictable and fluctuate based on a company's profitability.
CONMED Corp Analysis: Analyzing CONMED Corp's historical dividend chart can provide insights into the likelihood of maintaining a 2% annual yield.
